shenzhen salubris pharmaceuticals co., ltd.-j9九游会真人游戏第一
shenzhen salubris pharmaceuticals co., ltd.-j9九游会真人游戏第一
join us
九游会j9·(中国)真人游戏第一品牌
home page
about us
profile
affiliates/subsidiaries
development history
quality management
contact us
legal statement
adverse reaction report
science and technology
r&d platform
r&d pipeline
therapeutic field
international business
apis
finished products
medical device
download product list
contact
news center
news & trends
public information
news & trends
10
2023-10
new overseas clinical progress of jk07 for the treatment of chronic heart failure (hfref)
08
2023-10
sal0120 tablets for treatment of iga nephropathy approved for clinical trial
10
2023-08
vena cava filter system (saexten®) approved by nmpa
09
2023-06
enarodustat(恩那罗®) approved by nmpa for treatment of renal anemia (abstract) nmpa approved enarodustat(恩那罗®)
05
2023-02
the clinical progress of sal0119 tablets for the treatment of ankylosing spondylitis and rheumatoid arthritis
18
2023-01
progress of s086 for the treatment of mild to moderate primary hypertension
目前在第
1
页,
共有
9
页,
共有
49
条记录
1
2
3
4
5
下一页
最后一页
跳转到
页
网站地图